1. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis
   Bao-Wen Tian et al, 2023, Clinical & Experimental Metastasis CrossRef
2. Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis
   Juyue Zhou et al, 2023, Frontiers in Immunology CrossRef
3. Targeting tumor-associated macrophage: an adjuvant strategy for lung cancer therapy
   Lei Liu et al, 2023, Frontiers in Immunology CrossRef
4. Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
   Jeng-Shiuan Tsai et al, 2022, Pharmaceuticals CrossRef
5. Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
   Wei Zhang et al, 2023, Frontiers in Immunology CrossRef
6. Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy
   Chian-Wei Chen et al, 2023, Frontiers in Oncology CrossRef
7. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: Markers predicting immune-checkpoint inhibitor efficacy and immune-related adverse events
   Qiu-Yu Jiang et al, 2024, World Journal of Gastrointestinal Oncology CrossRef
8. Progress in the Study of Serum Markers to Predict the Efficacy of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
   颖 李, 2024, Advances in Clinical Medicine CrossRef
9. Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysis
   Hong-Rui Lu et al, 2023, Clinical and Translational Oncology CrossRef
10. Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab
    Lorena Incorvaia et al, 2023, Frontiers in Oncology CrossRef